| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Histopathology, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
2 National Cancer Institute, Bethesda, Maryland, MD 20892-1402 USA
Dr Shousha s.shousha{at}ic.ac.uk Aims—Prolactin plays an important role in the proliferation and differentiation of normal breast epithelium, and possibly in the development of breast carcinoma. The effects of prolactin are mediated by its receptor; thus, alteration in the expression of this receptor could be important in studying the biology of breast cancer. This investigation was aimed at comparing the expression of prolactin receptors in normal, benign, and malignant breast tissue.
Material/Methods—The expression of prolactin receptors was studied in paraffin wax embedded sections of 102 breast biopsies (93 female and nine male), using the monoclonal antibody B6.2, and the avidin–biotin immunoperoxidase technique. Six biopsies were normal, 34 had benign lesions, and 62 were malignant.
Results—In normal cases, prolactin receptor positivity was seen only on the luminal borders of the epithelial cells lining ducts and acini. In most benign lesions, variable degrees of luminal and cytoplasmic staining were seen. Cells showing apocrine metaplasia and florid regular ductal epithelial hyperplasia were mostly negative. In malignant cases, the staining pattern was mostly cytoplasmic and heterogeneous. Forty one of the 59 carcinomas in women showed a degree of positivity involving 10–100% of the tumour cells. A significant direct correlation was found between prolactin receptor and oestrogen receptor staining when only cases that scored more than 100/300 for the latter receptor, using the H scoring system, were considered (p = 0.0207). No correlation was found between prolactin receptors and progesterone receptors, patient's age, tumour size, tumour grade, or axillary lymph node status.
Conclusions—Prolactin receptors seem to be expressed at different cellular sites in normal, benign, and malignant breast epithelial cells. The receptor is expressed in more than two thirds of female breast carcinomas, suggesting that it may play a role in the pathogenesis of the disease. The positivity is correlated with moderate and strong staining for oestrogen receptors in tissue sections, but not with other prognostic factors.
Key Words: breast • breast carcinoma • male breast • prolactin receptors • oestrogen receptors
This article has been cited by other articles:
|
|
 |
|
  A. Plotnikov, Y. Li, T. H. Tran, W. Tang, J. P. Palazzo, H. Rui, and S. Y. Fuchs Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3{beta} Impairs Degradation of Prolactin Receptor Cancer Res., March 1, 2008; 68(5): 1354 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Harvey, D. J. Everett, and C. J. Springall Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol, March 1, 2008; 22(2 Suppl): 20 - 27. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M. Arendt and L. A. Schuler Prolactin Drives Estrogen Receptor-{alpha}-Dependent Ductal Expansion and Synergizes with Transforming Growth Factor-{alpha} to Induce Mammary Tumors in Males Am. J. Pathol., January 1, 2008; 172(1): 194 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Neilson, J. Zhu, J. Xie, M. G. Malabarba, K. Sakamoto, K.-U. Wagner, R. A. Kirken, and H. Rui Coactivation of Janus Tyrosine Kinase (Jak)1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Signal Transducer and Activator of Transcription (Stat)3 and Enhancement of Akt and Stat5a/b Pathways Mol. Endocrinol., September 1, 2007; 21(9): 2218 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Cheng, A. Imir, T. Suzuki, V. Fenkci, B. Yilmaz, H. Sasano, and S. E. Bulun SP1 and SP3 Mediate Progesterone-Dependent Induction of the 17beta Hydroxysteroid Dehydrogenase Type 2 Gene in Human Endometrium Biol Reprod, October 1, 2006; 75(4): 605 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P W Harvey, D J Everett, and C J Springall Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer Human and Experimental Toxicology, July 1, 2006; 25(7): 395 - 404. [Abstract] [PDF]
|
|
|
|
 |
|
 F E Utama, M J LeBaron, L M Neilson, A S Sultan, A F Parlow, K-U Wagner, and H Rui Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J. Endocrinol., March 1, 2006; 188(3): 589 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, P. Sluss, and S. E. Hankinson Association between Plasma Prolactin Concentrations and Risk of Breast Cancer among Predominately Premenopausal Women Cancer Res., February 15, 2006; 66(4): 2476 - 2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Albrektsen, I. Heuch, S. Thoresen, and G. Kvale Clinical Stage of Breast Cancer by Parity, Age at Birth, and Time Since Birth: A Progressive Effect of Pregnancy Hormones? Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 65 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Lu, T. M. Piazza, and L. A. Schuler Proteasomes Mediate Prolactin-induced Receptor Down-regulation and Fragment Generation in Breast Cancer Cells J. Biol. Chem., October 7, 2005; 280(40): 33909 - 33916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Saglam and B Can Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman J. Clin. Pathol., January 1, 2005; 58(1): 87 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, A. H. Eliassen, B. Rosner, P. Sluss, and S. E. Hankinson Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer Cancer Res., September 15, 2004; 64(18): 6814 - 6819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Lacroix, R-A Toillon, and G Leclercq Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics Endocr. Relat. Cancer, September 1, 2004; 11(3): 497 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Meng, C.-H. Tsai-Morris, and M. L. Dufau Human Prolactin Receptor Variants in Breast Cancer: Low Ratio of Short Forms to the Long-Form Human Prolactin Receptor Associated with Mammary Carcinoma Cancer Res., August 15, 2004; 64(16): 5677 - 5682. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
